TSTickerStarGet alerts

DataMEDS AI Reports Q3 2026 Revenue of $2.7M, Net Profit Per Share of $2.72

DataMEDS AI reported Q3 2026 revenue of $2.7 million, representing 50% sequential growth from Q2 2026 but down approximately 11% from Q3 2025 revenue of $3.0 million. The company delivered net profit of $10.5 million and diluted EPS of $2.72, compared to a net loss of $34.3 million and loss per share of $23.07 in Q3 2025, with the turnaround driven by debt extinguishment gains and reduced operating expenses. The company regained full compliance with Nasdaq listing standards on October 19, 2026.

Share this story

Key takeaways

  • Q3 2026 revenue of $2.7M up 50% sequentially from Q2 2026 ($1.8M) but down 11% year-over-year from Q3 2025 ($3.0M)

  • Q3 2026 net profit of $10.5M vs net loss of $34.3M in Q3 2025; EPS of $2.72 diluted vs loss of $23.07 per share year-over-year

  • Net profit driven by $19.1M gain on debt extinguishment; underlying operating loss was $3.4M

  • Nine-month 2026 revenue of $6.0M down 72% from $21.7M in nine-month 2025

  • Company regained full compliance with Nasdaq listing standards on October 19, 2026

  • Acquired Helomics Corporation cancer diagnostics laboratory in September 2026

  • Launched Health Lives Here mobile app partnered with NFL Alumni Health platform

Key metrics

Net revenuesQ3 2026
$2.7 milliondown approximately 11% from Q3 2025
Net revenuesNine months 2026
$6.0 milliondown 72% from nine months 2025
Net incomeQ3 2026
$10.5 millionfrom net loss of $34.3 million in Q3 2025
Net lossNine months 2026
$15.5 millionfrom net loss of $73.4 million in nine months 2025
Operating lossQ3 2026
$3.4 millionfrom operating loss of $31.5 million in Q3 2025
Diluted EPSQ3 2026
$2.72from loss of $23.07 per share in Q3 2025
Diluted EPSNine months 2026
($5.89)from loss of $58.78 per share in nine months 2025
Gain on debt extinguishmentQ3 2026
$19.1 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open Investor relations

Follow MEDS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert